Home » Topics » Regulatory » EMA

EMA
RSS

EMA committee begins safety review of Diane-35 and generics

Feb. 11, 2013

EMA grants accelerated assessment to trametinib application

Feb. 8, 2013

EMA approves label extension for Abilify

Feb. 6, 2013

French ANSM to suspend marketing of Diane-35 and generics for acne

Jan. 31, 2013

Prosensa's Duchenne muscular dystrophy products achieve orphan drug status

Jan. 30, 2013

Novartis receives positive CHMP opinion for Ilaris in acute gouty arthritis

Jan. 22, 2013

EMA confirms recommendation to suspend nicotinic acid/laropiprant

Jan. 21, 2013

CHMP recommends approval of Jetrea in Europe for vitreomacular traction

Jan. 21, 2013

Bosutinib receives positive CHMP opinion for conditional marketing authorization

Jan. 21, 2013

European CHMP set to discuss MAA for defibrotide

Jan. 18, 2013

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...